Multitude’s AMT-253 Shows Early Efficacy in Solid Tumors at ESMO
19 Oct 2025 //
PR NEWSWIRE
Multitude Therapeutics Reveals Positive Phase I/II Data
17 Oct 2025 //
PR NEWSWIRE
Multitude & Adcendo signed a licensing agreement for
06 Sep 2024 //
PRESS RELEASE
Adcendo And Multitude Therapeutics Partner On First-In-Class ADC
20 Aug 2024 //
PR NEWSWIRE

Market Place
Sourcing Support